Drug General Information |
Drug ID |
D0NO1A
|
Former ID |
DCL001152
|
Drug Name |
AT001/r84
|
Drug Type |
Antibody
|
Indication |
Cancer [ICD9: 140-229; ICD10:C00-C96]
|
Phase 1 |
[1]
|
Company |
Affitech
|
Target and Pathway |
Target(s) |
Vascular endothelial growth factor A |
Target Info |
|
[1]
|
KEGG Pathway
|
Ras signaling pathway
|
Rap1 signaling pathway
|
Cytokine-cytokine receptor interaction
|
HIF-1 signaling pathway
|
mTOR signaling pathway
|
PI3K-Akt signaling pathway
|
VEGF signaling pathway
|
Focal adhesion
|
Pathways in cancer
|
Proteoglycans in cancer
|
MicroRNAs in cancer
|
Renal cell carcinoma
|
Pancreatic cancer
|
Bladder cancer
|
Rheumatoid arthritis
|
NetPath Pathway
|
IL2 Signaling Pathway
|
EGFR1 Signaling Pathway
|
TGF_beta_Receptor Signaling Pathway
|
TSH Signaling Pathway
|
Leptin Signaling Pathway
|
FSH Signaling Pathway
|
PANTHER Pathway
|
Angiogenesis
|
VEGF signaling pathway
|
Pathway Interaction Database
|
Glypican 1 network
|
HIF-2-alpha transcription factor network
|
Beta3 integrin cell surface interactions
|
S1P3 pathway
|
Signaling events mediated by TCPTP
|
S1P1 pathway
|
Alpha9 beta1 integrin signaling events
|
Integrins in angiogenesis
|
VEGFR1 specific signals
|
HIF-1-alpha transcription factor network
|
Reactome
|
Platelet degranulation
|
Regulation of gene expression by Hypoxia-inducible Factor
|
VEGF ligand-receptor interactions
|
VEGF binds to VEGFR leading to receptor dimerization
|
WikiPathways
|
SIDS Susceptibility Pathways
|
Hypertrophy Model
|
Endochondral Ossification
|
Focal Adhesion
|
Differentiation Pathway
|
Bladder Cancer
|
Regulation of Hypoxia-inducible Factor (HIF) by Oxygen
|
Nifedipine Activity
|
Aryl Hydrocarbon Receptor
|
Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis
|
Integrated Pancreatic Cancer Pathway
|
Oncostatin M Signaling Pathway
|
Allograft Rejection
|
Integrated Breast Cancer Pathway
|
Signaling by VEGF
|
Heart Development
|
Angiogenesis
|
References |
REF 1 | Clinical pipeline report, company report or official report of Affitech (2011). |